Alexander C Fanaroff

List of Publications by Year
in descending order

79 papers	1,608 citations	331538 21 h-index	315616 38 g-index
84 all docs	84 docs citations	84 times ranked	2387 citing authors

#	Article	IF	Citations
1	Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Network Open, 2021, 4, e216139.	2.8	187
2	Does This Patient With Chest Pain Have Acute Coronary Syndrome?. JAMA - Journal of the American Medical Association, 2015, 314, 1955.	3.8	170
3	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA - Journal of the American Medical Association, 2019, 321, 1069.	3.8	144
4	Outcomes of PCI in Relation to ProceduralÂCharacteristics and OperatorÂVolumes inÂthe United States. Journal of the American College of Cardiology, 2017, 69, 2913-2924.	1.2	104
5	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	79
6	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum, 2021, 2, e214182.	1.0	58
7	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004755.	0.9	51
8	Randomized Trials Versus CommonÂSense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
9	Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e008227.	1.4	49
10	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. Circulation, 2019, 139, 458-472.	1.6	43
11	Geographic and Socioeconomic Disparities in Major Lower Extremity Amputation Rates in Metropolitan Areas. Journal of the American Heart Association, 2021, 10, e021456.	1.6	42
12	Kalirin Promotes Neointimal Hyperplasia by Activating Rac in Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 702-708.	1.1	40
13	G Proteinâ€“Coupled Receptor Kinase-5 Attenuates Atherosclerosis by Regulating Receptor Tyrosine Kinases and 7-Transmembrane Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 308-316.	1.1	38
14	Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. JAMA Cardiology, 2022, 7, 150.	3.0	37
15	Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Nonâ€“ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2017, 2, 36.	3.0	31
16	Association Between Cardiac Catheterization Laboratory Pre-Activation and Reperfusion Timing Metrics and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1837-1847.	1.1	29
17	Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012â€“2018. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008260.	0.9	27
18	Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Nonâ€“STâ€Segmentâ€“Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	26

#	Article	IF	Citations
19	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. International Journal of Cardiology, 2017, 241, 87-96.	0.8	24
20	Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATEâ€ACS Study. Journal of the American Heart Association, 2017, 6, .	1.6	23
21	Stroke prevention in atrial fibrillation: re-defining â€˜real-world dataâ€™ within the broader data universe. European Heart Journal, 2018, 39, 2932-2941.	1.0	22
22	An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004675.	0.9	20
23	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation, 2019, 139, 863-873.	1.6	18
24	Patient Selection for Advanced Heart Failure Therapy Referral. Critical Pathways in Cardiology, 2014, 13, 1-5.	0.2	17
25	Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. American Heart Journal, 2019, 215, 167-177.	1.2	17
26	New Approaches to Conducting Randomized Controlled Trials. Journal of the American College of Cardiology, 2020, 75, 556-559.	1.2	17
27	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus. Journal of the American College of Cardiology, 2017, 69, 2304-2313.	1.2	14
28	Competing Risks of Cardiovascular Versus Noncardiovascular Death During Longâ€Term Followâ€Up After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	1.6	14
29	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. Drug Safety, 2016, 39, 715-727.	1.4	12
30	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology, 2022, 79, 417-427.	1.2	12
31	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S.APractice With ISCHEMIA Trial Population. JACC: Cardiovascular Interventions, 2021, 14, 2344-2349.	1.1	11
32	High-quality evidence to inform clinical practice. Lancet, The, 2019, 394, 633-634.	6.3	10
33	Anticoagulation in COVID-19. Journal of the American College of Cardiology, 2020, 76, 1827-1829.	1.2	10
34	Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2015, 314, 1990.	3.8	9
35	Nonâ€“Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. Annual Review of Medicine, 2019, 70, 61-75.	5.0	9
36	Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice. Circulation: Cardiovascular Interventions, 2020, 13, e009179.	1.4	9

#	Article	IF	Citations
37	Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. Circulation: Cardiovascular Interventions, 2021, 14, e011232.	1.4	9
38	Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. American Heart Journal, 2019, 214, 184-193.	1.2	8
39	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	3.0	8
40	Clinical outcomes and need for intensive care after non-ST-segment-elevation myocardial infarction. European Journal of Internal Medicine, 2020, 76, 58-63.	1.0	8
41	Economic Considerations in Access to Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011489.	1.4	8
42	A Path Forward for Regenerative Medicine. Circulation Research, 2018, 123, 495-505.	2.0	6
43	Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair. American Heart Journal, 2021, 232, 1-9.	1.2	6
44	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. American Heart Journal, 2020, 226, 4-12.	1.2	6
45	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. European Heart Journal Supplements, 2022, 24, A19-A31.	0.0	6
46	Antiplatelet Therapy in Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 221-237.	0.2	5
47	Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. American Journal of Cardiology, 2019, 123, 1399-1405.	0.7	5
48	Radial Access for Peripheral Interventions. Interventional Cardiology Clinics, 2020, 9, 53-61.	0.2	5
49	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006182.	0.9	5
50	Recognising acute coronary syndrome. BMJ, The, 2022, 377, e069591.	3.0	5
51	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. American Heart Journal, 2014, 167, 466-471.	1.2	4
52	Association Between Intensive Care Unit Usage and Longâ€Term Medication Adherence, Mortality, and Readmission Among Initially Stable Patients With Nonâ€“STâ€Segmentâ€“Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e015179.	1.6	4
53	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction for Intensive Care Unit Admission. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007602.	0.9	4
54	Rural-Urban Disparities in Cardiovascular Outcomes. Journal of the American College of Cardiology, 2022, 79, 280-282.	1.2	4

#	Article	IF	Citations
55	Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. European Heart Journal, 2020, 41, 4505-4507.	1.0	3
56	Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events. Trials, 2020, 21, 323.	0.7	3
57	Seeking patient-centered trial outcomes: The case for days alive out of hospital. American Heart Journal, 2022, 248, 172-174.	1.2	3
58	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATEâ€ACS (Treatment With ADP Receptor) Tj ETQq0 0 0 rgBT /Overlock 1	1.6	2
59	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) Tj ETQq1 1 0.784314 rgBT /Ove		
60	Independence of clinical events committees: A consensus statement from clinical research organizations. American Heart Journal, 2022, 248, 120-129.	1.2	2
61	Percutaneous Coronary Intervention in Acute Coronary Syndrome and Cardiogenic Shock. JACC: Cardiovascular Interventions, 2022, 15, 887-889.	1.1	2
62	Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a Highâ€Risk Population. Journal of the American Heart Association, 2015, 4, .	1.6	1
63	ANTIPLATELET THERAPY CHANGES FOR MI PATIENTS WITH RECURRENT ISCHEMIC EVENTS: INSIGHTS INTO CONTEMPORARY PRACTICE FROM THE TRANSLATE-ACS STUDY. Journal of the American College of Cardiology, 2017, 69, 24.	1.2	1
64	PERIPHERAL ARTERY DISEASE AND TRANSCATHETER AORTIC VALVE REPLACEMENT OUTCOMES: A REPORT FROM THE STS/TVT REGISTRY. Journal of the American College of Cardiology, 2017, 69, 991.	1.2	1
65	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circulation: Heart Failure, 2021, 14, e008277.	1.6	1
66	Adding Precision to Defining Bleeding and Ischemic Risk With PCI in CancerÂPatients. JACC: Cardiovascular Interventions, 2021, 14, 1106-1108.	1.1	1
67	Patient and Staff Perceptions of Universal Severe Acute Respiratory Syndrome Coronavirus 2 Screening Prior to Cardiac Catheterization and Electrophysiology Laboratory Procedures. Circulation: Cardiovascular Interventions, 2020, 13, e009975.	1.4	1
68	Hospital-Level Percutaneous Coronary Intervention Performance With SimulatedÂRisk Avoidance. Journal of the American College of Cardiology, 2021, 78, 2213-2217.	1.2	1
69	The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Progress in Cardiovascular Diseases, 2021, 69, 11-17.	1.6	1
70	Conundrums for Atrial Fibrillation Management in Older Adults. Current Geriatrics Reports, 2015, 4, 368-376.	1.1	0
71	PATTERNS OF ANGINA AND ANTIANGINAL MEDICATION USE AMONG PATIENTS FOLLOWING MI TREATED WITH PCI: INSIGHTS FROM TRANSLATE-ACS. Journal of the American College of Cardiology, 2017, 69, 1.	1.2	0
72	Physiologic Assessment of Stent Deployment. Circulation: Cardiovascular Interventions, 2019, 12, e007955.	1.4	0

#	Article	IF	Citations
73	Association between intensive care unit utilization for patients with nonâ€“ST-segment elevation myocardial infarction and patient experience. American Heart Journal, 2021, 231, 32-35.	1.2	0
74	Anticoagulation dosing in atherosclerotic cardiovascular disease: Is less more?. European Journal of Internal Medicine, 2021, 83, 8-9.	1.0	0
75	Antithrombotic Regimens in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e010331.	1.4	0
76	Reporting of Percutaneous Coronary Interventions Site-Specific Mortalityâ€”Reply. JAMA Cardiology, 2021, 6, 1344.	3.0	0
77	Lack of Association Between Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement Outcomes in New York Hospitals. Circulation: Cardiovascular Interventions, 2021, 14, e010750.	1.4	0
78	1 Month of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 2073-2075.	1.2	0
79	Epidemiology and Outcomes of Patients Readmitted to the Intensive Care Unit After Cardiac Intensive Care Unit Admission. American Journal of Cardiology, 2022, 170, 138-146.	0.7	0